{"schema_version":"secwatch.filing_event.v1","accession":"0001698530-24-000067","form_type":"8-K","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.645120+00:00","generated_at":"2026-06-01T04:08:01.404052+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Exicure reports Q1 net loss of $0.8M; cash only $0.2M by May 31, going concern","bullets":["Cash and equivalents $0.4M at March 31, 2024, falling to ~$0.2M by May 31.","Received $0.7M loan from DGP Co., Ltd. after May 31; 6% interest, 10-month maturity.","Revenue of $0.5M from patent license for cavrotolimod (hepatitis) with private biopharma.","Net loss improved to $0.8M from $4.4M YoY due to cost cuts and license revenue.","Company states existing cash insufficient; substantial near-term financing needed."],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-24-000067","json":"https://secwatch.observer/filing/0001698530-24-000067.json","markdown":"https://secwatch.observer/filing/0001698530-24-000067.md","text":"https://secwatch.observer/filing/0001698530-24-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853024000067/0001698530-24-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853024000067/xcur-20240617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:08:01.404052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}